OBJECTIVE: To explore the association between polymorphisms of the sterol regulatory element-binding transcription factor (SREBF) gene and ischaemic stroke. METHODS: The SREBF1c 54G>C and SREBPF2 1784G>C genotypes were assessed using restriction fragment length polymorphism analysis in 446 Han Chinese ischaemic stroke patients and 355 Han Chinese control subjects without cerebrovascular disease. RESULTS: The frequencies of the SREBF2 1784G>C CC genotype and the C allele were significantly higher in the ischaemic stroke group than in controls. Patients with ischaemic stroke who had the SREBF2 1784G>C CC genotype had significantly lower high-density lipoprotein (HDL) levels, compared with ischaemic stroke patients and control subjects with the GC or GG genotypes. Multivariate logistic regression analysis revealed a significant positive association between SREBF2 1784G>C and ischaemic stroke; an inverse association was observed between HDL level and risk of ischaemic stroke. CONCLUSIONS: The CC genotype of the SREBF2 1784G>C polymorphism was associated with an increased risk of ischaemic stroke, possibly through decreasing the HDL level, which was inversely associated with the risk of ischaemic stroke.
Introduction
Despite considerable research into the pathogenesis of cerebrovascular disease (CVD), stroke remains a substantial cause of mortality in the Western world (the third most common cause in the USA). 1 The clinical management of stroke is largely supportive, although evidence is emerging for the benefit of early pharmacological intervention. A significant proportion of patients remain disabled or die even when these therapies are used. 1 Accordingly, stroke prevention is likely to offer the most effective method of reducing the incidence of stroke. 1 Effective prevention depends on a reliable means of identifying and treating the risk factors associated with stroke, and possibly targeting preventative measures at high-risk groups. Accumulating evidence suggests that the aetiology of stroke is multifactorial, resulting from a complex series of interactions between genes and the X Jin, F Zeng, N Zhang et al. SREBF polymorphisms associated with risk of ischaemic stroke environment. The outward expression of the disease, or the disease phenotype, is in part the product of gene-gene and geneenvironment interactions. 2 Hypercholesterolaemia is a well recognized risk factor for atherosclerosis, 3 which is a pivotal process in the development of ischaemic stroke. 1 Sterol regulatory element-binding transcription factors (SREBFs) are a group of important regulators of hypercholesterolaemia. The SREBF family consists of three isoforms: SREBF-1a, SREBF-1c and SREBF-2. 4 SREBF-1a and SREBF-1c are derived from a single gene through the use of alternative promoters. 4 SREBF-1a has potent transcriptional activity for genes involved in the synthesis of cholesterol, fatty acids and triglycerides, 5 SREBF-1c has transcriptional activity for genes involved in fatty acid and triglyceride synthesis, 6, 7 and SREBF-2 preferentially activates the transcription of genes involved in cholesterol synthesis. 8 Unlike SREBF-1a, SREBF-1c is regulated by nutritional conditions and plays a central role in the nutritional regulation of lipogenesis as a dominant isoform in liver and adipose tissue. 9 SREBF-2 is considered to be deeply involved in the regulation of cholesterol metabolism. 8, 10 A number of gene promoter analyses have revealed that the expression of most genes for cholesterol biosynthetic enzymes -squalene synthase in particularis regulated largely by SREBF-2. 8, 10 It has been reported that 54G>C, a common single nucleotide polymorphism (SNP) located in exon 18c (rs2297508) of the SREBF1c gene, is associated with obesity and type 2 diabetes mellitus. 11, 12 In addition, the SNP (1784G>C) in the SREBF2 gene is reportedly associated with early-stage carotid atherosclerosis and may be critical for the development of polygenic hypercholesterol aemia. 4, 13 While most studies are currently focused on the association between SREBF polymorphisms and coronary artery disease or metabolic disorders, the present study explored the association between SREBF polymorphisms and ischaemic stroke in a Han Chinese population.
Patients and methods

STUDY POPULATION
Between September 2007 and September 2009, this case-control study collected blood samples from consecutive Han Chinese ischaemic stroke patients at the time of their presentation to the Department of Neurology, Xiangya Hospital, China. Blood samples were also collected from Han Chinese subjects without CVD, who were attending the Xiangya Hospital for routine examinations; these acted as control subjects. All ischaemic stroke cases were confirmed by X-ray, computed tomography or magnetic resonance imaging. For the ischaemic stroke patients, the exclusion criteria were as follows: cardiogenic ischaemic stroke, or ischaemic stroke caused by arterial inflammation; trauma; blood diseases; drug use; cancer; cerebral vascular malformation or arterial aneurysm; severe liver or kidney dysfunction; autoimmune disease; pregnancy; haemorrhage after stroke; treatment with lipid-lowering medication or oestrogen within the previous 6 months. For control subjects, the exclusion criteria were as follows: severe liver, kidney or blood disease; autoimmune disease; cancer; pregnancy; treatment with lipid-lowering medication or oestrogen within the previous 6 months.
Blood samples were collected into heparinized tubes at the beginning of the study and stored at -86°C if not used immediately.
The study was approved by the Ethics X Jin, F Zeng, N Zhang et al. SREBF polymorphisms associated with risk of ischaemic stroke Committee of Central South University, Changsha, China. Written informed consent was obtained from all ischaemic stroke patients and control subjects before the start of the study.
RFLP ANALYSIS OF THE SREBF GENOTYPE
Genomic DNA from blood specimens (1 ml) was isolated according to standard proteinase K digestion and phenolchloroform extraction procedures. Genotyping of the SREBF1c 54G>C (rs2297508) and SREBF2 1784G>C SNPs was performed using restriction fragment length polymorphism (RFLP) analysis, as described previously. 4, 14 Primer sequences used for the polymerase chain reaction (PCR) were as follows: SREBF1c forward 5′-CTGTGCT ACTTTGCCTTTTGC-3′, reverse 5′-GTCAGTC CATCCTCCCGTG-3′ to generate a 406 base pair (bp) amplicon. SREBF2 forward 5′-GCCAGTGACCATTAACACCTTTTGA-3′, reverse 5′-TCGTCTTCAAAGCCTGCCTCAG TGGCTGGC-3′ to generate a 247 bp amplicon.
The PCR reaction mix included 200 µM dNTPs, 1.5 mM magnesium chloride, 0.2 U AmpliTaq Gold ® , and 1 × reaction buffer pH 9.0 (Applied Biosystems, Foster City, CA, USA) plus 200 µM of each primer, and was carried out using a GeneQ™ Thermal Cycler (Bulldog Bio. Inc., Rochester, NY, USA) according to the manufacturer's instructions. Glyceraldehyde 3-phosphate dehydrogenase was used as the internal control. The cycling programme involved preliminary denaturation at 95°C for 1 min, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s and elongation at 72°C for 60 s, followed by a final elongation step at 72°C for 10 min.
The resulting PCR products were digested with XmnI for SREBF1c and MspI for SREBF2 (New England Biolabs Inc., Beverly, MA, USA) overnight at 37°C, and the digestion products were analysed by 2% agarose gel electrophoresis followed by visualization with ethidium bromide and ultraviolet light. The accuracy of the RFLP assay was verified by dye-terminator sequencing of the respective DNA region in 25 DNA samples from ischaemic stroke patients and in 25 control subjects, as described previously, 15 using a commercially available Thermo Sequenase™ Cy5 Dye Terminator Sequencing Kit (GE Healthcare Biosciences, Piscataway, NJ, USA).
CLINICAL ASSESSMENTS AND LABORATORY ANALYSES
Body mass index (BMI) and smoking and drinking status were determined for all patients and controls. Smokers were defined as those who smoked a mean of at least 1 packet/day for over 1 year and did not include patients who had stopped smoking within 1 year. Patients who had stopped smoking at least 1 year before the study started were classed as nonsmokers. Alcohol use was defined as consumption of a mean of 120 g/day of alcohol for over 1 year, not including patients who had stopped within 1 year. Patients' blood samples were used to analyse fasting blood glucose, total cholesterol (TC), triglyceride (TG), highdensity lipoprotein (HDL) and low-density lipoprotein (LDL) levels, as described previously. 11
STATISTICAL ANALYSES
Values for all continuous variables are expressed as mean ± SD. Hardy-Weinberg equilibrium analysis of genotype distribution in controls was carried out by a χ 2 goodnessof-fit test. Differences in the genotype and allele frequencies between the ischaemic stroke patients and the non-CVD control X Jin, F Zeng, N Zhang et al. SREBF polymorphisms associated with risk of ischaemic stroke subjects were determined using the χ 2 -test. Logistic regression analysis was performed to assess the odds ratio (OR) and 95% confidence interval (CI). Between-group comparisons were performed with the Student's t-test after tests of normality and equality of variances. Comparisons of the means among the genotype groups were performed with oneway analysis of variance followed by post hoc pairwise comparisons, using the least significant difference method. All of the statistical analyses were performed with SAS ® software package, version 9.1.3 (SAS Institute Inc., Cary, NC, USA). A P-value < 0.05 was considered to be statistically significant.
Results
A total of 446 Han Chinese ischaemic stroke patients and 355 Han Chinese control subjects without CVD participated in this study. As shown in Table 1 , there were no significant differences between patients and controls in age, gender, smoking, alcohol use, TG, TC and LDL levels. Baseline BMI (P = 0.02 after adjusting for other variables), systolic and diastolic blood pressure (P < 0.001 for both comparisons), and the frequency of hypertension (P < 0.001), diabetes mellitus (P = 0.003) and coronary heart disease (P < 0.001) were all significantly higher in the ischaemic stroke group versus the control group. The mean HDL level was significantly higher in the control group than in the ischaemic stroke group (P < 0.001).
The genotype and allele distributions for SREBF1c 54G>C and SREBF2 1784G>C in the control group and the ischaemic stroke group are summarized in Table 2 . The frequencies of the polymorphism genotypes X Jin, F Zeng, N Zhang et al. SREBF polymorphisms associated with risk of ischaemic stroke were in Hardy-Weinberg equilibrium in the control group. There was no significant difference in SREBF1c 54G>C genotype and allele frequencies between the two groups. The CC genotype and C allele frequencies of the SREBF2 1784G>C polymorphism were significantly higher in patients with ischaemic stroke compared with control subjects (P < 0.0001 for both comparisons). The frequencies of the GG genotype and G allele were significantly lower in patients than in controls (P < 0.0001; Table 2 ).
Laboratory data showed that ischaemic stroke patients with a SREBF2 1784G>C CC genotype had significantly lower HDL levels compared with ischaemic stroke and control subjects with a GC or GG genotype (P < 0.05 for all comparisons; Table 3 ). In contrast, there was no significant difference in the laboratory data between patients with different SREBF1c 54G>C genotypes (Table 4) .
Multivariate logistic regression analysis showed that hypertension, hyperlipidaemia and BMI were closely associated with ischaemic stroke (Tables 5 -7 ). The SREBF2 1784G>C ( Table 6 ) polymorphism but not the SREBF1c 54G>C (Table 5 ) polymorphism showed a significant association with ischaemic stroke (P = 0.048), which was abolished by additional adjustment for the blood lipids LDL, TG and TC (Table 7) . HDL was inversely associated with the risk of ischaemic stroke (P = 0.046) ( Table 7 ).
Discussion
Stroke is the second most common fatal disease after malignant tumours, with an annual estimate of more than 2 million new Comparisons of the means among the genotype groups were performed with one-way analysis of variance followed by post hoc pairwise comparisons using the least significant difference method. FBS, fasting blood sugar; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein. No statistically significant between-group differences after one-way analysis of variance followed by post hoc pairwise comparisons using the least significant difference method (P > 0.05).
FBS, fasting blood sugar; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
X Jin, F Zeng, N Zhang et al. SREBF polymorphisms associated with risk of ischaemic stroke cases and at least 1.5 million deaths in China. 16 In particular, about 80 -90% of patients with stroke have an ischaemic stroke. 17 Thus, ischaemic stroke is a major public health issue in China. 16 The Han Chinese population was selected for the present study because it accounts for 90% of the population in China and 19% of the global population. 18 The present study found that the CC genotype of the SREBF2 1784G>C polymorphism was associated with an increased risk of ischaemic stroke, possibly through decreasing the HDL level, which was inversely associated with the risk of ischaemic stroke. This was the first study to explore the association between SREBF polymorphisms and ischaemic stroke risk.
The SREBF1c 54G>C polymorphism (i.e.
Variable
Odds ratio 95% Confidence interval
SREBF1c 54G>C In the logistic regression analysis, ischaemic stroke diagnosis (yes/no) was used as the dependent variable. Variable inclusion and exclusion criteria were α in = 0.10 and α out = 0.15. a P = 0.048; b P = 0.02; c P < 0.0001. BMI, body mass index.
TABLE 5:
Multivariate logistic regression analysis for the association between sterol regulatory element-binding transcription factor (SREBF)1c 54G>C gene polymorphism and ischaemic stroke risk in a Han Chinese population X Jin, F Zeng, N Zhang et al. SREBF polymorphisms associated with risk of ischaemic stroke the SREBF-1c G952G protein) is reportedly associated with obesity, type 2 diabetes mellitus and hypercholesterolaemia, 11,12,19 -23 which are known independent risk factors for ischaemic stroke. 3,24 -29 No SREBF1c 54G>C genotype was found to be directly associated with ischaemic stroke in the present study.
The SREBF-2 G595A protein, which corresponds to SREBF2 1784G>C, is a critical factor for the development of polygenic hypercholesterolaemia. 13 The frequency of the SREBF2 1784G>C CC genotype in the present study was significantly higher in the ischaemic stroke group than in the control group, indicating that the CC genotype is associated with an increased risk of ischaemic stroke. In multivariate logistic regression analysis, the SREBPF2 1784G>C polymorphism was an independent risk factor for ischaemic stroke, suggesting that the CC genotype contributes to the incidence of ischaemic stroke independently of its hypercholesterolaemia-promoting effects. It is noteworthy that the ischaemic stroke patients with a SREBF2 1784G>C CC genotype had significantly lower HDL levels compared with the ischaemic stroke patients or control subjects with a GC or GG genotype. The decreased HDL level may have accounted for the association between the CC genotype and ischaemic stroke in the present study, since additional adjustment for the HDL level in the logistic regression analysis abolished the significant association between SREBF2 1784G>C and ischaemic stroke. In contrast, Bowman et al. 30 reported that decreased HDL was not significantly associated with the risk of ischaemic stroke. This lack of consensus may be due to differences between the two study populations.
Plasma HDL levels are inversely correlated with cardiovascular risk, and HDL is known to remove cholesterol that has accumulated in cells. 31 In the logistic regression analysis, ischaemic stroke diagnosis (yes/no) was used as the dependent variable. Variable inclusion and exclusion criteria were α in = 0.10 and α out = 0.15. a P < 0.0001; b P = 0.046. BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 33 Several studies have reported the importance of hepatic ABCA1 for maintaining plasma HDL levels, suggesting that the liver is a major producer of HDL. 35 Activation of the SREBFs, especially SREBF-2, may enhance transcription of the ABCA1 gene in the liver through a functional SREBF response site in the upstream region of exon 2 35 which, in turn, increases the plasma level of HDL. The present study suggested that the CC genotype of SREBF2 1784G>C polymorphism may result in decreased transactivation of the ABCA1 gene by SREBF-2, resulting in decreased plasma levels of HDL. Further studies are needed to understand the underlying mechanisms and confirm the association between HDL and the risk of ischaemic stroke.
In conclusion, the CC genotype of SREBF2 1784G>C was found to be associated with an increased risk of ischaemic stroke, possibly via decreased HDL levels, which are inversely associated with the risk of ischaemic stroke. The present study provides important reference data for future stroke prevention based on individual genetic profiles, and suggests that increasing HDL levels may help to prevent ischaemic stroke.
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